Corcept Therapeutics Incorporated
LSE: 0I3Q.L0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- London Stock Exchange
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- CEO
- Joseph K. Belanoff
- Employees
- 500
- Headquarters
- Menlo Park, United States
- IPO year
- 2018
- Market cap
- $5.4B
- Website
- https://www.corcept.com
Loading 0I3Q…
Loading profile data…Frequently asked questions about 0I3Q
What does Corcept Therapeutics Incorporated (0I3Q.L) do?
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients...
Where does 0I3Q.L trade?
Corcept Therapeutics Incorporated (0I3Q.L) trades on the London Stock Exchange.
What sector is 0I3Q.L in?
Corcept Therapeutics Incorporated (0I3Q.L) operates in the Healthcare sector, specifically in the Medical - Pharmaceuticals industry.
Who is the CEO of Corcept Therapeutics Incorporated?
Joseph K. Belanoff is the chief executive officer of Corcept Therapeutics Incorporated (0I3Q.L).
Where is Corcept Therapeutics Incorporated headquartered?
Corcept Therapeutics Incorporated is headquartered in United States.
Does 0I3Q.L pay a dividend?
Corcept Therapeutics Incorporated (0I3Q.L) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 0I3Q.L go public?
Corcept Therapeutics Incorporated (0I3Q.L) completed its initial public offering in 2018.